Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported...
-
Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
-
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- CenTrak, a leader in real-time location system (RTLS) solutions, today announced expanded integration capabilities with two major healthcare...
-
$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investorThe...
-
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- "Very promising results." That is how REGENXBIO, Inc. (NASDAQ: RGNX) characterized its RGX-111 gene therapy candidate as recently as January 2025. By...
-
Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation...
-
Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and...
-
Austin, TX, USA, March 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Intracranial Pressure Monitoring Devices Market Size, Trends and Insights By...
-
SHERMAN OAKS, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Dr. Austin Harris, a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is...
-
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following...